Patents Examined by Gregg Polansky
  • Inhibitors and methods of inhibiting bacterial and viral pathogens
    Patent number: 9233087
    Abstract: Compounds, pharmaceutical compositions and methods for treating viral and bacterial infections, by administering certain thiourea compounds, specifically acylthiourea, carboximidoylthiourea and S-alkyl isothiourea derivatives and analogs, in therapeutically effective amounts are disclosed.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: January 12, 2016
    Assignee: SIGA TECHNOLOGIES, INC
    Inventors: Robert D. Allen, Sean M. Amberg, Dongcheng Dai, James R. Burgeson, Dennis E. Hruby
  • 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
    Patent number: 9227946
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: January 5, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • Hepatitis C virus inhibitors
    Patent number: 9212168
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 2, 2012
    Date of Patent: December 15, 2015
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Daniel D. Long, Robert Murray McKinnell, Lan Jiang, Mandy Loo, Kassandra Lepack, Lori Jean Van Orden, Gavin Ogawa
  • Antimicrobial compounds and methods of making and using the same
    Patent number: 9193731
    Abstract: The present invention relates generally to the field of antimicrobial compounds and to methods of making and using them. These compounds are useful for treating, preventing, and reducing the risk of microbial infections in humans and animals.
    Type: Grant
    Filed: October 15, 2010
    Date of Patent: November 24, 2015
    Assignee: Melinta Therapeutics, Inc.
    Inventors: Erin M. Duffy, Ashoke Bhattacharjee, Hardwin O'Dowd, Marco DeVivo, Zoltan F. Kanyo, Jacek G. Martinow, Ik-Hyeon Paik, Matthew H. Scheideman, Sandra Sinishtaj, Brian T. Wimberly, Yusheng Wu
  • PSMA binding ligand-linker conjugates and methods for using
    Patent number: 9193763
    Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.
    Type: Grant
    Filed: August 15, 2008
    Date of Patent: November 24, 2015
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Sumith A. Kularatne
  • Methods for enhancing muscle performance and tone
    Patent number: 9192601
    Abstract: Provided herein are methods and compositions for improving muscle performance and increasing endurance. Agonists of AMP-activated protein kinase (AMPK) and agonists of peroxisome proliferator-activated receptor delta (PPAR?) can be used in such treatments.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: November 24, 2015
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Vihang A. Narkar, Reuben J. Shaw, Michael Downes, Ruth T. Yu
  • Spiroindolinepiperidine derivatives
    Patent number: 9174987
    Abstract: Insecticidal, acaricidal, nematicidal or molluscicidal compounds of formula (I) wherein Y is a single bond, C?O, C?S or S(O)q where q is 0, 1 or 2; and R1, R2, R3, R4, R8, R9 are R10 are as defined in the claims or salts or N-oxides thereof, processes for preparing them and compositions containing them.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: November 3, 2015
    Assignees: Syngenta Limited, Syngenta Participations AG
    Inventors: David John Hughes, Paul Anthony Worthington, Charles Adam Russell, Eric Daniel Clarke, James Edward Peace, Mark Richard Ashton, Thomas Stephen Coulter, Richard Spurring Roberts, Louis-Pierre Molleyres, Fredrik Cederbaum, Jerome Cassayre, Peter Maienfisch
  • Pharmaceutical composition for treating and/or preventing a pathology associated with an obsessional behavior or with obesity
    Patent number: 9168250
    Abstract: This invention relates to the use of a ligand of the 5-HT4 receptor or of a pharmaceutically acceptable salt of this ligand and to a nucleic acid coding for a 5-HT4 receptor or of a functionally equivalent receptor for a drug for treating and/or preventing a pathology associated with an obsessional behavior such as anorexia, bulimia and the addiction to drugs of abuse or obesity. The invention also relates to a method for identifying a compound that is biologically active in the treatment and/or the prevention of a pathology associated with an obsessional conduct or obesity including: a) placing the 5-HT4 receptor or a functionally equivalent receptor in contact with this biologically active compound, and b) the determination of whether this biologically active compound is capable of modulating the basal activity of the 5-HT4 receptor or of a functionally equivalent receptor.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: October 27, 2015
    Assignee: Centre National de la Recherche Scientifique-CNRS
    Inventor: Valerie Compan
  • Heterocyclic compounds containing an indole core
    Patent number: 9150577
    Abstract: Disclosed are novel compounds which inhibit RSK, methods of making such compounds and pharmaceutical compositions comprising such compounds. Also disclosed are methods of treating RSK2 regulated disorders using compounds of the invention.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 6, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephen J. Boyer, Donghong Amy Gao, Xin Guo, Thomas Martin Kirrane, Jr., Christopher Ronald Sarko, Roger John Snow, Fariba Soleymanzadeh, Yunlong Zhang
  • Methods and compositions for treating cornelia de lange syndrome
    Patent number: 9138424
    Abstract: Disclosed are methods and compositions for treating subjects with Cornelia de Lange Syndrome (CdLS). Specifically disclosed are methods for using Indomethacin or Acemetacin to treat subjects with CdLS. Also disclosed are methods for identifying compounds beneficial for the treatment of CdLS using an assay based on the expression of NIPBL or NIPBL homologous or orthologous genes. Also disclosed is a method of identifying compounds beneficial for the treatment of CdLS based on administering a test compound to Drosophila lava with reduced expression of Nipbl, and determining the normalization of CdLS phenotypes.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: September 22, 2015
    Assignees: Saint Louis University, Washington University
    Inventors: Dale Dorsett, Justin Fay
  • 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
    Patent number: 9125910
    Abstract: This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt
  • 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
    Patent number: 9125909
    Abstract: This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Andre Faldt, Arne Mork, Heidi Lopez de Diego, Rene Holm, Tine Bryan Stensbol
  • 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HTand 5-HTactivity for the treatment of cognitive impairment
    Patent number: 9125908
    Abstract: 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients.
    Type: Grant
    Filed: April 1, 2014
    Date of Patent: September 8, 2015
    Assignee: H. Lundbeck A/S
    Inventors: Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt, Rene Holm, Heidi Lopez de Diego
  • Steroids having 7-oxygen and 17-heteroaryl substitution-3
    Patent number: 9115168
    Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 7?-hydroxy-17-(3-pyridyl)-androst-4,16-diene-3-one and other androst-4,16-diene compounds substituted at the 17-position with a heterocycle moiety and at the 3- and 7-positions with a hydroxyl, ester, ether or other disclosed moiety.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: August 25, 2015
    Assignee: NEURMEDIX, INC.
    Inventor: James M. Frincke
  • Steroids having 7-oxygen and 17-heteroaryl substitution-2
    Patent number: 9102702
    Abstract: The invention relates to the use of compounds to ameliorate or treat a condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3?,7?-dihydroxy-17-(3-pyridyl)-androst-5,16-diene and other androst-5,16-diene compounds substituted at the 17-position with a heterocycle moiety and at the 3- and 7-positions with a hydroxyl, ester, ether or other disclosed moiety.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: August 11, 2015
    Assignee: Neurmedix Inc.
    Inventor: James M. Frincke
  • Substituted pyrimidinone-phenyl-pyrimidinyl compounds
    Patent number: 9056110
    Abstract: The present disclosure provides pyrimidinone-phenyl-pyrimidinyl compounds useful in the treatment of p38 kinase mediated diseases, such as lymphoma and inflammatory disease, having the structure of Formula (I): wherein R1, R2, R3, R4 and R5 are as defined in the detailed description; pharmaceutical compositions comprising at least one of the compounds; and methods for treating p38 kinase mediated diseases using the compound.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: June 16, 2015
    Assignee: CONFLUENCE LIFE SCIENCES, INC.
    Inventors: Shaun R. Selness, Balekudru Devadas, Susan L. Hockerman, Joseph B. Monahan
  • Pyrazine derivatives as ENaC blockers
    Patent number: 9050339
    Abstract: Compounds of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, are useful for treating diseases mediated by blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: October 22, 2012
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Gurdip Bhalay, Lee Edwards, Catherine Howsham, Peter Hunt, Nichola Smith
  • Alpha adrenergic receptor modulators
    Patent number: 9040532
    Abstract: Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure. Methods of making, using and formulating these compounds are described.
    Type: Grant
    Filed: October 6, 2010
    Date of Patent: May 26, 2015
    Assignee: Allergan, Inc.
    Inventors: Ken Chow, Liming Wang, Wenkui K. Fang, Evelyn G. Corpuz, Santosh C. Sinha, Daniel W. Gil, Mohammad I. Dibas, John E. Donello
  • Interaction control of cationic biocides using labile anionic polyelectrolytes
    Patent number: 9040510
    Abstract: Methods of inhibiting the uptake of cationic biocides into medical devices such as contact lenses and implants are described. Methods of stabilizing emulsions containing cationic biocides are also described. In particular, the present invention provides for the use of polymers acting as labile anionic polyelectrolytes to reversibly bind cationic biocides. The reversible binding can reduce the deleterious effects of cationic biocides while maintaining biocidal activity. Preferred polymers include galactomannan and polyvinyl alcohol.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: May 26, 2015
    Assignee: Alcon Research, Ltd.
    Inventors: Howard Allen Ketelson, Ryan Desousa, Nissanke L. Dassanayake, Mary E. Luck
  • Pharmaceutical composition containing low-substituted hydroxypropyl cellulose
    Patent number: 9034860
    Abstract: Disclosed is a pharmaceutical composition containing a compound represented by the general formula (I) below or a pharmacologically acceptable salt thereof, while having improved dissolvability. Specifically disclosed is a pharmaceutical composition containing (A) a compound represented by the general formula (I) below or a pharmacologically acceptable salt thereof, and (B) a low-substituted hydroxypropyl cellulose.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: May 19, 2015
    Assignees: DAIICHI SANKYO COMPANY, LIMITED, UBE INDUSTRIES, LTD.
    Inventors: Tomoyuki Watanabe, Kazuko Maeda